Our Deepest Appreciation to All Shareholders Who Stand Behind Us.

In light of the recent challenges brought by our clinical trial results, we understand that the outcome was not what our shareholders had originally hoped for. Yet during this difficult period, we have continued to receive your encouragement and support through greeting cards, emails, and phone calls. Every message and every gesture has been deeply appreciated, becoming an important source of strength that drives us forward.

Drug development is a long and demanding journey. It requires rigorous testing, repeated verification, and unwavering perseverance before it can bring meaningful change to patients waiting for new treatment options. Despite the challenges ahead, TWi Biotechnology has never given up and has never wavered in its commitment to science and to life.

We will continue to invest, to refine our work, and to pursue better outcomes—honoring the trust placed in us by every shareholder and partner.

Although the road ahead remains challenging, your support makes us stronger, more determined, and more confident in moving toward the day when we can bring hope to patients and to society.

Once again, we extend our deepest gratitude to all shareholders who continue to stand behind us.